The long-term outcomes of alternating chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a multiinstitutional phase II study

English version České info

Abstract:
To examine the long-term outcomes of alternating chemoradiotherapy (ALCRT) for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to assess the efficacy of ALCRT for NPC. Patients with stage IIB to IVB, ECOG PS 0–2, 18–70 years-old, and sufficient organ function were eligible for this study. First, chemotherapy, consisting of 5-fluorouracil (800 mg/m² per 24 h on days 1–5) and cisplatin (100 mg/m² per 24 h on day 6), was administered, then a wide field of radiotherapy (36 Gy/20 fraction), chemotherapy, a shrinking field of radiotherapy (34 Gy/17 fraction), and chemotherapy were performed alternately. Between December 2003 and March 2006, 90 patients in 25 facilities were enrolled in this study, 87 patients were finally evaluated. A total of 67 patients (76.1%) completed the course of treatment. The overall survival and the progression-free survival rates at 5 years were 78.04% (95% CI: 69.1~87.0%), and 68.74% (95% CI: 58.8~78.7%), respectively. The long-term outcomes of ALCRT for NPC were thought to be promising. ALCRT will be considered to be a controlled trial to compare therapeutic results with those of concurrent chemoradiotherapy for NPC.

Keywords:
5-fluorouracil; alternating chemoradiotherapy; cisplatin; nasopharyngeal carcinoma; phase 2 study

Autoři: Nobukazu Fuwa ¹; Takeshi Kodaira ²; Takashi Daimon ³; Tomokazu Yoshizaki ^4,*
Působiště autorů: Department of Radiology, Hyogo Ion Beam Medical Center, Hyogo, Japan ¹; Department of Radiation Oncology, Aichi Cancer Center, Aichi, Japan ²; Department of Biostatistics, Hyogo College of Medicine, Hyogo, Japan ³; Department of Otorhinolaryngology, Kanazawa University, Ishikawa, Japan ⁴
Vyšlo v časopise: Cancer Medicine 2015; 4(8)
Kategorie: Original Research
prolekare.web.journal.doi_sk: https://doi.org/10.1002/cam4.469

© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Souhrn

Keywords:
5-fluorouracil; alternating chemoradiotherapy; cisplatin; nasopharyngeal carcinoma; phase 2 study

Zdroje

1.Ho, J. H. C. 1978. An epidemiological and clinical study of nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 4:183–197.

2.Wang, D. C., W. M. Cai, and V. C. Hu. 1988. Long term survival of 1035 cases of nasopharyngeal carcinoma. Cancer 61:2328–2341.

3.Curado, M. P., B. Edwards, H.R. shin, H. storm, J. Ferlay, M. Heanue, and P. Boyle, eds. 2007. Cancer incidence in five continents, Vol. 9. IARC Scientific Publications No. 160, International Agency for Research on Cancer. Lyon, France.

4.Xie, X., H. Wang, H. Jin, S. Ouyang, J. Zhou, J. Hu, et al. 2013. Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma. Radiat. Oncol.8:117.

5.Mesic, J. B., G. H. Fletcher, and H. Goepfert. 1981. Megavoltage irradiation of epithelial tumors of the nasopharynx. Int. J. Radiat. Oncol. Biol. Phys. 7:447–453.

6.Wang, C. C., and J. E. Meyer. 1971. Radiotherapeutic management of the carcinoma of the nasopharynx. Analysis of 170 patients. Cancer 28:566–570.

7.Al-Sarraf, M., M. LeBlanc, P. G. Giri, K. K. Fu, J. Cooper, T. Vuong, et al. 1998. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup Study 0099. J. Clin. Oncol. 16:1310–1317.

8.Fuwa, N., Y. Ito, T. Kodaira, A. Matsumoto, M. Kamata, K. Furutani, et al. 2001. Therapeutic results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: its usefulness and controversial points. Jpn. J. Clin. Oncol. 31:589–595.

9.Fuwa, N., Y. Ito, T. Kodaira, A. Matsumoto, M. Kamata, K. Furutani, et al. 2007. Treatment results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil. A pahse II study. Oral Oncol. 43:948–955.

10.Lee, A. W., S. Y. Tung, R. K. Ngan, R. Chappell, D. T. Chua, T. X. Lu, et al. 2011. Factors contributing to the efficacy of concurrent adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur. J. Cancer 47:656–666.

11.Zhang, L., C. Zhao, B. Ghimire, M. H. Hong, Q. Liu, Y. Zhang, et al. 2010. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials. BMC Cancer 15:558.

12.Chen, L., C. S. Hu, X. Z. Chen, G. Q. Hu, Z. B. Cheng, Y. Sun, et al. 2012. Cocurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomized controlled trial. Lancet Oncol.13:163–171.

13.Liang, Z. G., X. D. Zhu, Z. R. Zhou, S. Qu, Y. Q. Du, Y. M. Jiang, et al. 2012. Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials. Asian Pac. J. Cancer Prev. 13:5747–5752.

14.Boscolo-Rizzo, P., G. Tirelli, M. Mantovani, V. Baggio, V. Lupato, G. Spinato, et al. 2014. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice. Eur. Arch. Otorhinolaryngol. 2014 Nov 4. [Epub ahead of print] PMID: 25367705.

15.Hui, E. P., B. B. Ma, S. F. Leung, A. D. King, F. Mo, M. K. Kam, et al. 2009. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J. Clin. Oncol. 27;242–249.

16.Liang, Z. G., X. D. Zhu, A. H. Tan, Y. M. Jiang, S. Qu, F. Su, et al. 2013. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or without adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: meta-analysis of 1,096 patients from11 randomized controlled trials. Asian Pac. J. Cancer Prev. 14:515–521.

17.Blanchard, P., J. Bourhis, B. Lacas, M. R. Posner, J. B. Vermorken, J. J. Hernandez, et al. 2013. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J. Clin. Oncol. 31:2854–2860.

18.John, M. J., M. S. Flam, S. S. Legha, and T. L. Phillips. 1993. Chemoradiation: An Integrated Approach to Cancer Treatment. Lea & Febiger, Philadelphia.

19Langendijk, J. A., C. R. Leemans, J. Buter, et al. 2004. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature.J. Clin. Oncol. 22:4604–4612.

20.Chan, A. T., S. F. Leung, R. K. Ngan, P. M. Teo, W. H. Lau, W. H. Kwan, et al. 2005. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J. Natl Cancer Inst. 97:536–539.

21.Kawashima, M., N. Fuwa, M. Myojin, K. Nakamura, T. Toita, S. Saijo, et al. 2004. A multi-institutional survey of the effectiveness of chemotherapy combined with radiotherapy for patients with nasopharyngeal carcinoma. Jpn. J. Clin. Oncol. 34:569–583.

22.Ou, S. H., J. A. Zell, A. Ziogas, and H. Anton-Culver. 2007. Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Ann. Oncol. 18:29–35.

23.Lee, N., J. Harris, A. S. Garden, W. Straube, B. Glisson, P. Xia, et al. 2009. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J. Clin. Oncol. 27:3784–3790.